Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 4, 2013, Pages 368-375

  Ali, Sumbul ^a   Chen, Ji An ^a,b   Garcia, Jose M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cachexia; Cancer; Ghrelin; Ghrelin mimetics; Growth hormone

Indexed keywords

GHRELIN; GHRELIN RECEPTOR; GROWTH HORMONE;

ANIMAL; APPETITE; CACHEXIA; DISEASE MODEL; DRUG EFFECT; HUMAN; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; QUALITY OF LIFE; REVIEW; SECRETION (PROCESS); SKELETAL MUSCLE; WEIGHT GAIN;

ANIMALS; APPETITE; CACHEXIA; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; GHRELIN; GROWTH HORMONE; HUMANS; MUSCLE, SKELETAL; NEOPLASMS; QUALITY OF LIFE; RECEPTORS, GHRELIN; WEIGHT GAIN;

EID: 84887934424     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000012     Document Type: Review

References (51)

1. Bowers CY, Momany F, Reynolds GA, et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 1980; 106:663-667.
2. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273:974-977.
3. Sun Y, Garcia JM, Smith RG. Ghrelin and growth hormone secretagogue receptor expression in mice during aging. Endocrinology 2007; 148:1323-1329.
4. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
5. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87:2988.
6. Guillory B, Splenser A, Garcia J. The role of ghrelin in anorexia-cachexia syndromes. Vitam Horm 2013; 92:61-106.
7. Porporato PE, Filigheddu N, Reano S, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013; 123: 611-622.
8. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159:1029-1037.
9. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489-495.
10. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141:4325-4328.
11. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992.
12. Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005; 29:1130-1136.
13. Smith RG, Jiang H, Sun Y. Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol Metab 2005; 16:436-442.
14. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120:337-345.
15. Dickson SL, Egecioglu E, Landgren S, et al. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol 2011; 340:80-87.
16. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012; 118:4785-4794.
17. Yasuda T, Masaki T, Kakuma T, Yoshimatsu H. Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. Neurosci Lett 2003; 349:75-78.
18. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90:2920-2926.
19. Moses AW, Slater C, Preston T, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90:996-1002.
20. Plata-Salaman CR. Brain cytokine production and action in anorexia and cachexia. Cytokine 2001; 15:1-3.
21. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20:604-612.
22. Batista ML Jr, Peres SB, McDonald ME, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine 2012; 57:9-16.
23. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin-and activationinduced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114:57-66.
24. Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm IGF Res 2009; 19:187-197.
25. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37:649-661.
26. Garcia JM, Scherer T, Chen JA, et al. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in MALE mice. Endocrinology 2013; 154:3118-3129.
27. DeBoer MD, Zhu XX, Levasseur P, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007; 148:3004-3012.
28. Ding J, List EO, Bower BD, Kopchick JJ. Differential effects of growth hormone versus insulin-like growth factor-I on the mouse plasma proteome. Endocrinology 2011; 152:3791-3802.
29. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30:152-177.
30. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol 2008; 154:557-568.
31. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009; 19:267-273.
32. Akamizu T, Takaya K, Irako T, et al. Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 2004; 150:447-455.
33. Vestergaard ET, Djurhuus CB, Gjedsted J, et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab 2008; 93:438-444.
34. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-0677, an orally active growth hormone secretagogue reverses diet-induced catabolism. J Clin Endocrinol Metab 1998; 83:320-325.
35. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149:601-611.
36. White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94:1198-1206.
37. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007; 12:594-600.
38. Broglio F, Boutignon F, Benso A, et al. EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J Endocrinol Invest 2002; 25:RC26-RC28.
39. Piccoli F, Degen L, MacLean C, et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab 2007; 92:1814-1820.
40. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2832-2836.
41. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98:300-308.
42. Lundholm K, Gunnebo L, Korner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized doubleblind study. Cancer 2010; 116:2044-2052.
43. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21:129-137.
44. Cassoni P, Papotti M, Catapano F, et al. Specific binding sites for synthetic growth hormone secretagogues in nontumoral and neoplastic human thyroid tissue. J Endocrinol 2000; 165:139-146.
45. Cassoni P, Papotti M, Ghe C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001; 86:1738-1745.
46. Hanada T, Toshinai K, Kajimura N, et al. Anticachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003; 301:275-279.
47. Wang W, Andersson M, Iresjo BM, et al. Effects of ghrelin on anorexia in tumorbearing mice with eicosanoid-related cachexia. Int J Oncol 2006; 28:1393-1400.
48. Matsumura T, Arai M, Yonemitsu Y, et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol 2010; 45:300-307.
49. Takeda H, Muto S, Nakagawa K, et al. Rikkunshito as a ghrelin enhancer. Methods Enzymol 2012; 514:333-351.
50. Fujitsuka N, Asakawa A, Uezono Y, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Translat Psychiatr 2011; 1:e23.
51. Mintz L. Dln101 a naturally occurring ghrelin splice variant for the treatment of cachexia. Abstract presented at the 7th Cachexia Conference, Milan, Italy; 2011.